Loading clinical trials...
Loading clinical trials...
The MELAcare Study: a Randomized Controlled Trial of a New Method for Surveillance of Melanoma Patients
The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma. The investigators will compare different tools for patient support and education combined with clinician supported skin self-examination (SSE) to the current standard-of-care. The hypothesis is that meta-cognitive strategies and clinician supported SSE can lower fear of cancer recurrence (FCR) and promote effective SSE on a regular basis without compromising the detection of new primary melanomas and/or metastases.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Herlev and Gentofte Hospital
Copenhagen, Denmark
Start Date
March 9, 2022
Primary Completion Date
June 1, 2024
Completion Date
March 1, 2028
Last Updated
June 26, 2023
378
ESTIMATED participants
The MelaCare intervention
OTHER
Lead Sponsor
Herlev and Gentofte Hospital
Collaborators
NCT05039801
NCT06391099
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions